arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Design Therapeutics, Inc.

DSGN

$13.79 ▲ +0.21 (+1.58%) at close

7 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Design Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $790.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -29.5% ↘

FCF / Share $-0.95 ↘

Trailing P/E —

Price / Book 3.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-69.79M

↓ -40.7% —

FCF / Share Free cash flow per share

$-0.95

↓ -23.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-38.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	26.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-4.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-48.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-40.7% Weak ↓ Weak Declining Year-over-year change in net income	25.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-5.6% Weak ↑ Weak Improving Year-over-year change in net income	-78.2% Weak Weak Year-over-year change in net income	-329.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-23.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	26.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-12.0% Weak Weak Year-over-year change in free cash flow	-39.3% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-29.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	58.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-35.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-22.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-32.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-319%)	-20.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-237%)	-24.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	-19.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-229%)	-9.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	73.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+388%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-347.08x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-16.86M	$-22.56M	$-21.20M	$-26.50M	$-298.57M	$-2.38M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.00	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.22	$-0.88	$-1.19	$-1.14	$-0.77	—	—
Free Cash Flow per Share (USD)	$-0.95	$-0.77	$-1.05	$-0.94	$-0.67	—	—
Book Value per Share (USD)	$3.52	$4.27	$4.92	$5.86	$6.89	$-0.71	—
Tangible Book Value per Share (USD)	$3.52	$4.27	$4.92	$5.86	$6.89	$-0.71	—
Basic Weighted Avg Shares (shares)	57.33M	56.59M	55.98M	55.71M	45.94M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$210.73M	$239.58M	$274.96M	$324.34M	$380.15M	$33.90M	—
Total Equity (USD)	$212.50M	$242.10M	$277.69M	$327.31M	$382.13M	$-11.31M	$-3.64M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	—	—	—	—	$226.00K	—
Depreciation Expense (USD)	$622.00K	$596.00K	$537.00K	$406.00K	$129.00K	$5.00K	—
Net Income, GAAP (USD)	$-69.79M	$-49.59M	$-66.86M	$-63.31M	$-35.53M	$-8.28M	—
Operating Cash Flow (USD)	$-54.36M	$-43.10M	$-58.56M	$-51.32M	$-29.38M	$-8.67M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Design Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DSGN with peers